IFNA1 and COVID-19: Previously, we identified neutralizing anti-IFNα autoAbs in the plasmas of ∼10% of individuals from a cohort of patients suffering from severe COVID-19 (“COVID ICU” cohort), as well as in ∼0.85% of individuals over the age of 65 years in a well-treated cohort of people living with HIV-1 (“Aged” cohort) (Busnadiego et al., 2022; Fernbach et al., 2024).